Australian government proposes "tough new standards" for Innovation Patents
Australia’s federal government said in media release this week that it is "considering tough new standards for Innovation Patents in order to discourage large companies from abusing the IP system."
Parliamentary Secretary for Industry and Innovation Mark Dreyfus made the announcement which said that, at present, innovation patents protect simple inventions and improvements to existing technologies. “They also require an innovative step, whereas standard patents require an inventive step,” he pointed out.
Innovation patents were introduced in 2001 to encourage intellectual property (IP) protection for small to medium enterprises. Since the Delnorth (2009) decision in the Federal Court, relatively obvious minor improvements to inventions have been patentable.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze